A novel antituberculosis agent exhibits potent clinical efficacy and good safety profile: an open-label, randomized-controlled, multicenter, phase 2a trial
一种新型抗结核药物展现出显著的临床疗效和良好的安全性:一项开放标签、随机对照、多中心 IIa 期试验
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02517-z
Chu, Naihui; Nie, Wenjuan; Du, Juan; Wang, Manni; Ma, Liping; Wang, Qingfeng; Wang, Jun; Hu, Xiaomeng; Wu, Jin; Lu, Yu; Huang, Mailing; Wei, Yuquan; Wang, Zhenling; He, Jian-Qing; Ding, Zhenyu; Wei, Xiawei